Open AccessAdding chemotherapy to TKI: can we improve first-line treatment for EGFR-mutated NSCLC patients?
Author(s) -
Francesco Passiglia,
Antonio Russo
Publication year - 2016
Publication title -
translational cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.254
H-Index - 30
eISSN - 2219-6803
pISSN - 2218-676X
DOI - 10.21037/tcr.2016.12.32
Subject(s) - gefitinib , pemetrexed , medicine , oncology , clinical endpoint , hazard ratio , lung cancer , epidermal growth factor receptor , chemotherapy , non small cell lung cancer (nsclc) , population , progression free survival , randomized controlled trial , cancer , confidence interval , cisplatin , environmental health , a549 cell
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom